

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM349572

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
UCB Pharma, S.A.		07/18/2015	CORPORATION: BELGIUM
RECEIVING PARTY DATA			
Name:	UCB Biopharmaa SPRL		
Street Address:	Allée de la Recherche		
Internal Address:	60 B-1070		
City:	Brussels		
State/Country:	BELGIUM		
Entity Type:	société privée à responsabilité limitée: BELGIUM		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	3665183	KEPPRA XR	
CORRESPONDENCE DATA			
Fax Number:	2027218250		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2027218227		
Email:	wlp@wenderoth.com		
Correspondent Name:	Wenderoth, Lind & Ponack, L.L.P.		
Address Line 1:	1030 15th Street, NW		
Address Line 2:	Suite 400 East		
Address Line 4:	Washington, D.C. 20005		
ATTORNEY DOCKET NUMBER:	TM06-117		
NAME OF SUBMITTER:	Rebecca Gan		
SIGNATURE:	/Rebeccah Gan/		
DATE SIGNED:	07/29/2015		
Total Attachments: 2			
source=2015 07 18 - KEPPRA XR - US - EXECUTED TRADEMARK ASSIGNMENT#page1.tif			
source=2015 07 18 - KEPPRA XR - US - EXECUTED TRADEMARK ASSIGNMENT#page2.tif			

OP \$40.00 3665183

TRADEMARK ASSIGNMENT

WHEREAS, UCB Pharma, S.A. (hereinafter "Assignor"), a corporation of Belgium, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels BELGIUM, owns the mark and registration thereof for U.S. Trademark Registration No. 3,665,183 for the mark KEPPRA XR for "Pharmaceutical preparations acting on the central nervous system" in Class 5 (hereinafter "the Mark"), as depicted in **Schedule A**; and


WHEREAS, UCB Biopharma SPRL (hereinafter "Assignee"), a société privée à responsabilité limitée of BELGIUM, having its principal place of business at Allée de la Recherche, 60 B-1070, Brussels, BELGIUM, desires to acquire all right, title and interest in the Mark and the registration thereof; and

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign to Assignee all right, title and interest in and to the Mark, including all common law rights, registrations or applications therefor, all rights of Assignor to petition, sue or otherwise seek and recover damages, profits and any other remedy (monetary, injunctive, declaratory or other), in the United States and anywhere, for any past, present or future infringement, conversion or misappropriation of, or other injury, offense, violation, breach of duty or wrong relating to the Mark, together with the goodwill of the Mark and the goodwill of the business associated with the Mark, effective as of the date of execution.

IN WITNESS WHEREOF, Assignor executed this Assignment this 18th day of July, 2015.

UCB Pharma, S.A.

18 JUL. 2015



Date

Signature

Anna RICHON

Name

Proxy & Legal Representative

Title



SCHEDULE A

<u>MARK</u>	<u>U.S. TRADEMARK REGISTRATION NUMBER</u>	<u>REGISTRATION DATE</u>	<u>GOODS/SERVICES</u>
KEPPRA XR (standard character form)	3,665,183	August 4, 2009	Pharmaceutical preparations acting on the central nervous system in Class 5